RT Journal Article
SR Electronic
T1 The tumor burden of metastatic colorectal cancer patients at initial diagnosis, pre- versus post-Covid-19 lockdown
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2021.03.17.21253408
DO 10.1101/2021.03.17.21253408
A1 Thierry, AR
A1 Pastor, B
A1 Pisareva, E
A1 Ghiringhelli, F
A1 Bouche, O
A1 De La Fouchardière, C
A1 Vanbockstael, J
A1 Smith, D
A1 François, E
A1 Dos Santos, M
A1 Botsen, D
A1 Ellis, S
A1 Fonck, M
A1 Andre, T
A1 Guardiola, E
A1 Khemissa, F
A1 Linot, B
A1 Martin-Babau, J
A1 Rinaldi, Y
A1 Assenat, E
A1 Clavel, L
A1 Dominguez, S
A1 Gavoille, C
A1 Sefrioui, D
A1 Pezzella, V
A1 Mollevi, C
A1 Ychou, M
A1 Mazard, T
YR 2021
UL http://medrxiv.org/content/early/2021/03/24/2021.03.17.21253408.abstract
AB Background The COVID-19 pandemic led to a significant reduction in the provision of screening, case identification and hospital referrals to cancer patients. To our knowledge, no study has yet correlated quantitatively the consequences of these limitations for cancer patient management. This study evaluates the implications of such reductions for patients newly diagnosed with metastatic colorectal cancer (mCRC) in both the pre- and post-lockdown periods.Methods We examined 80 newly identified mCRC patients from 18 different clinical centers. These cases come from the screening procedure of a clinical trial which is using circulating DNA (cirDNA) analysis to determine their RAS and BRAF status.Results The tumor burden as evaluated by the median total plasma cirDNA concentration showed a statistically higher level in patients diagnosed post-lockdown compared to those diagnosed pre-lockdown (119.2 versus 17.3 ng/mL; p<0.0001). In order to link tumor burden to survival, we compared the survival of these mCRC patients with previous studies in which cirDNA was examined in the same way (median survival, 16.2 months; median follow up, 48.7 months, N=135). Given the poor survival rate of mCRC patients with high cirDNA levels (14.7 vs 20.0 and 8.8 vs 19.3 months median survival when dichotomizing the cohort by the median cirDNA concentration 24.4 and 100 ng/mL, respectively), our study points to the potential deleterious consequences of the COVID-19 pandemic.Conclusions Recognizing that our exploratory study offers a snapshot of an evolving situation, our observations nonetheless clearly highlight the need to determine actions which would minimize delays in diagnosis during the ongoing and future waves of COVID-19.Competing Interest StatementThe authors have declared no competing interest.Clinical TrialThis is an unplanned study based upon the starting data from the UCGI 28 PANIRINOX study (NCT02980510/EudraCT #2016-001490-33)Funding StatementUnicancer, (Paris), and the support of AMGEN. B. Pastor was partially supported by SIRIC Montpellier Cancer Grant INCa_Inserm_DGOS_12553, and AR Thierry by INSERM.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:UCGI 28 PANIRINOX study (NCT02980510/EudraCT #2016-001490-33) protocol was approved by the French national health authorities (ANSM) and by the ethical committee Sud-Mediterranee IV, Montpellier.All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesThe data are freely available